Manchester Intermittent and Daily Diet Type 1 Diabetes App Study (MIDDAS-Type 1)
NCT04674384
Recruiting
To assess the safety, acceptability and feasibility of testing Intermittent Low Energy Diet (ILED) and Continuous Low Energy Diet (CLED) programmes for 12 weeks in a real life setting with people with T1D and obesity.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/09/2023
Locations: Manchester University NHS Foundation Trust, Manchester, Greater Manchester
Conditions: Type 1 Diabetes, Obesity
Register for Updates
Clinical Effectiveness of iReadMore for People With Alexia
NCT04849091
Recruiting
iReadMore will provide an app-based therapy for people with pure or central alexia. This study aims to test the clinical effectiveness of iReadMore for improving reading accuracy and speed in real world users of the therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2023
Locations: Institute of Neurology, University College London, London, Not set
Conditions: Stroke, Brain Injuries, Aphasia, Alexia, Dementia
Register for Updates
RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease
NCT05392894
Recruiting
The purpose of this clinical trial is to evaluate the clinical and cost effectiveness of Haploidentical Stem Cell Transplantation (SCT) for adults with severe sickle cell disease (SCD), who have failed other therapies or are intolerant of existing therapies or require chronic transfusions to prevent on-going complications of SCD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2023
Locations: King's College Hospital, London, Not set
Conditions: Sickle Cell Disease
Register for Updates
Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)
NCT02069509
Recruiting
This is a multi-centre, multi-national, prospective, observational study of Friedreich's Ataxia (FRDA) with a control group to: * obtain natural history data on individuals affected by FRDA * relate clinical assessments and results from proteomic analyses * expedite identification and recruitment of participants for clinical trials * develop and validate sensitive and reliable outcome measures for detecting onset and change over the natural course of FRDA which may also be potential outcome mea... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/05/2023
Locations: Medical University Innsbruck, Department of Neurology, Innsbruck, Not set +15 locations
Conditions: Friedreich's Ataxia
Register for Updates
Compassion-Focused Therapy for Distressing Mood Swings: A Case Series
NCT05860101
Recruiting
The goal of this case series is to investigate whether a brief compassion-focused intervention is a safe, acceptable and feasible therapy for clients with bipolar affective disorder. The secondary questions are whether a brief compassion focused intervention for BPD clients is associated with changes in bipolar mood symptoms and/ or with changes in psychological processes linked to mood symptoms in bipolar, including: Self-compassion, perfectionism, social comparison and social safeness. Four vi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2023
Locations: Institute of Psychiatry, Psychology & Neuroscience, London, Not set
Conditions: Bipolar Affective Disorder
Register for Updates
Trans People Living With HIV Throughout Europe
NCT03922269
Recruiting
The project will study a European cohort of individuals identifying themselves as transgender or non-binary and living with HIV. The study will collect both qualitative data on this cohort and clinical data over an 18 month period. The study will investigate the success of HIV treatment for this cohort through the primary outcome measure of HIV viral load recorded in routine blood tests. The results from this study will assist in informing future HIV treatment guidelines on the monitoring of H... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2023
Locations: Servizio Sanitario Nazionale Regione Piemonte Azienda Sanitaria Locale "Citta di Torino" Department of Medical Sciences, University of Turin, Torino, Not set +3 locations
Conditions: HIV Infections, Gender Identity, Human Immunodeficiency Virus
Register for Updates
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
NCT04333108
Recruiting
The purpose of this study is to evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients suffering from smouldering or indolent systemic mastocytosis with severe symptoms of mast cell mediator release, unresponsive to optimal symptomatic treatment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/03/2023
Locations: Centre Hospitalier Universitaire d'Amiens, Amiens, Not set +16 locations
Conditions: Indolent Systemic Mastocytosis
Register for Updates
The Accuracy of Sonotubometry to Assess the Eustachian Tube
NCT05740384
Recruiting
The Eustachian tube (ET) connects the middle ear with the throat and is important for maintaining a healthy middle ear. Sonotubometry is a new method to measure how well the ET works by using sound. A speaker is placed at the nostril and a microphone records sound in the external ear canal. The ET is closed at rest and opens with swallowing. This is measured as an increase in sound measured in the external ear by sonotubometry. Previous research has not proven that sonotubometry is reliable eno... Read More
Gender:
ALL
Ages:
Between 16 years and 64 years
Trial Updated:
05/02/2023
Locations: Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire
Conditions: Eustachian Tube Dysfunction
Register for Updates
Bioavailability of N-acylethanolamines: an Ileostomy Study (NAE Study)
NCT05845229
Recruiting
The endocannabinoids (ECs) and N-acylethanolamines (NAEs) are a group of endogenous lipid mediators which have a pleiotropic activity in the body modulating several biological pathways such as: appetite cues, food intake, blood pressure, inflammation, glycaemia, cognition and immunity. The ECs consist of N-arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG). They may have agonist activity on cannabinoid receptors CB1 and CB2 which are located in the central nervous system (CNS) and... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/02/2023
Locations: Human Intervention Studies Unit, Ulster University, Coleraine, Co.Londonderry
Conditions: Healthy Nutrition
Register for Updates
Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester
NCT05099237
Recruiting
The EMBRaCE-GM study is a multi-cohort trial designed to efficiently evaluate the range of wearable vital signs monitors that could be used to support patients during cancer treatment. The aims of the study are to determine * to determine if continuous vital signs monitoring is feasible during cancer treatment * to determine if such monitoring is acceptable to patients undergoing cancer treatment * to determine what insights could be made with the data obtained A multi-cohort study is essenti... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
05/02/2023
Locations: Manchester University NHS Foundation Trust, Manchester, Not set
Conditions: Colorectal Cancer, Lung Cancer, Hematological Cancer, CAR T-Cell Therapy
Register for Updates
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
NCT03662126
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: The Kirklin Clinic of UAB Hospital, Birmingham, Alabama +190 locations
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Register for Updates
Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression
NCT04359745
Recruiting
Glioblastoma is the most aggressive kind of brain cancer and leads on average to 20 years of life lost, more than any other cancer. MRI images of the brain are taken before the operation, and every few months after treatment, to see if the cancer regrows. It can be hard for doctors to tell if what they see in these images represent growing cancer or a sideeffect of treatment. The similarity of the appearance of the treatment side-effects to cancer is confusing and is known as "pseudoprogression"... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/20/2023
Locations: Royal Sussex County Hospital, Brighton and Sussex University Hospitals NHS Trust, Brighton, Not set +14 locations
Conditions: Glioblastoma
Register for Updates